8-K: Aprea Therapeutics Reports Q2 2025 Results, Clinical Progress

Aprea Therapeutics reported second quarter 2025 financial results and provided clinical updates for its lead oncology programs, APR-1051 and ATRN-119, showing early signs of disease control and tumor shrinkage.

Summary

• Aprea Therapeutics reported financial results for the second quarter ended June 30, 2025.
• Cash and cash equivalents were $16.5 million as of June 30, 2025, a decrease from $22.8 million as of December 31, 2024.
• The company's operating loss for Q2 2025 was $3.4 million, an improvement from $3.8 million in Q2 2024.
• Net loss for Q2 2025 was $3.2 million ($0.53 per basic share), compared to $3.5 million ($0.58 per basic share) for the comparable period in 2024.
• Research and Development (R&D) expenses decreased to $1.9 million in Q2 2025 from $2.6 million in Q2 2024.
• General and Administrative (G&A) expenses decreased to $1.6 million in Q2 2025 from $1.9 million in Q2 2024.
• In the Phase 1 ACESOT-1051 trial for the WEE1 inhibitor APR-1051, early evidence of disease control was observed, with three patients achieving stable disease (one in 70mg cohort, two in 100mg cohort), including an HPV-positive head and neck squamous cell carcinoma patient with a 5% tumor reduction.
• In the Phase 1/2a ABOYA-119 trial for the ATR inhibitor ATRN-119, early activity was observed, with seven patients achieving stable disease, including three patients showing meaningful tumor shrinkage (7%, 14%, and 21%) at the 550 mg twice daily dose.
• Dose limiting toxicity was observed in two patients at 550 mg twice daily for ATRN-119, leading to current dosing at 400 mg twice daily for further optimization.

Sentiment

Score: 6

Explanation: The filing presents a cautiously optimistic outlook. While financial losses persist and cash is decreasing, the company has extended its cash runway into Q2 2026. Crucially, both lead clinical programs show early signs of activity and favorable tolerability profiles, which are positive indicators for early-stage oncology assets. The dose-limiting toxicity for ATRN-119 is a common and manageable event in dose escalation. The potential for future capital through warrant exercise is also a positive, albeit contingent, funding mechanism. The overall sentiment is positive given the early clinical progress and financial management, but tempered by the inherent risks of clinical development and ongoing losses.

Positives

• Early evidence of clinical activity and disease control observed in both lead oncology programs, APR-1051 and ATRN-119.
• APR-1051 demonstrated an encouraging tolerability profile in its ongoing Phase 1 trial.
• ATRN-119 showed meaningful tumor shrinkage in three patients in its Phase 1/2a trial.
• Cash and cash equivalents of $16.5 million are projected to be sufficient to meet operating expenses and capital expenditure requirements into Q2 2026.
• Operating loss and net loss decreased in Q2 2025 compared to Q2 2024, indicating improved financial efficiency.
• R&D and G&A expenses decreased year-over-year, primarily due to reduced study start-up activities and personnel costs.
• A translational research collaboration with MD Anderson Cancer Center for APR-1051 preclinical results showed potent single-agent activity and significant anti-tumor synergy with antiPD-1 therapies in HPV+ HNSCC models.
• The company possesses a strong intellectual property portfolio, including multiple granted patents and pending applications for its ATR and WEE1 inhibitors.

Negatives

• The company reported a net loss of $3.2 million for the second quarter ended June 30, 2025.
• Cash and cash equivalents decreased from $22.8 million as of December 31, 2024, to $16.5 million as of June 30, 2025, reflecting ongoing cash burn.
• Dose limiting toxicity was observed in two patients at the 550 mg twice daily dose for ATRN-119, necessitating a dose adjustment to 400 mg twice daily.

Risks

• The success, timing, and cost of ongoing and anticipated clinical trials are uncertain.
• There is a risk regarding the ability to fully fund disclosed clinical trials, which assumes no material changes to currently projected expenses.
• Futility analyses, presentations at conferences, and data reported in abstracts are not necessarily indicative of the final results of ongoing clinical trials.
• The understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results from development programs may be inaccurate.
• The company's ability to continue as a going concern is subject to various factors.
• There are inherent risks and uncertainties related to regulatory submissions and achieving market acceptance of current and planned products and services.
• Forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions or by known or unknown risks and uncertainties.

Future Outlook

Aprea Therapeutics anticipates releasing additional safety and efficacy data for both APR-1051 (ACESOT-1051 study) and ATRN-119 (ABOYA-119 study) in the second half of 2025. Completion of the APR-1051 dose-escalation phase and identification of the recommended Phase 2 dose for ATRN-119 are expected in the first half of 2026. The company also plans to submit an abstract for APR-1051 to a major oncology conference. Future arms of both trials may explore combination therapies. Cash and cash equivalents are projected to fund operations into Q2 2026.

Management Comments

• "We are pleased with our progress in 2025, as emerging data from both of our lead programs demonstrate evidence of clinical activity."
• "Overall, these early signs of clinical validation continue to strengthen our confidence in the potential of our DDR assets and to deliver meaningful therapeutic advances for patients with cancer."

Industry Context

Aprea Therapeutics operates in the precision oncology space, focusing on synthetic lethality and DNA Damage Response (DDR) inhibition. This approach aims to selectively kill cancer cells with specific mutations while minimizing harm to healthy cells, potentially reducing toxicity compared to traditional chemotherapy. The company's WEE1 and ATR inhibitors target emerging pathways for cancer cell death, building on scientific innovation in the field. The company highlights the high unmet medical need in cancers with Cyclin E over-expression and DDR-related gene mutations.

Comparison to Industry Standards

• **WEE1 Inhibitors (APR-1051 vs. Competitors):** Aprea aims to solve tolerability challenges seen with other WEE1 inhibitors like AstraZeneca's Adavosertib (AZD-1775), which was discontinued due to its tolerability profile despite showing substantial single-agent activity (e.g., 29.4% ORR in recurrent uterine serous carcinoma, 33% in high-grade serous ovarian cancer with CCNE1 overexpression).
• APR-1051 is presented as highly potent and selective, with minimal off-target inhibition of PLK1, PLK2, and PLK3 (e.g., >150-fold difference in PLK1 inhibition IC50 compared to Zentalis's Azenosertib (ZN-c3)), which is associated with reduced cytotoxic effects and potential for improved safety (e.g., sepsis-induced intestinal barrier dysfunction).
• Preclinical data suggest favorable PK properties and negligible inhibition of hERG channels for APR-1051, potentially avoiding QT prolongation AEs reported with some competitor WEE1 inhibitors.
• **ATR Inhibitors (ATRN-119 vs. Competitors):** ATRN-119 is highlighted as the 'first and only macrocyclic ATR inhibitor,' suggesting potential advantages in increased selectivity, improved tolerability, and more efficacious dosing compared to first-generation acyclic ATR inhibitors.
• Competitors like AstraZeneca's AZD6738, Bayer's BAY1895344, and Repare's RP-3500 have reported Grade 3 hematological toxicities such as anemia, neutropenia, and thrombocytopenia.
• ATRN-119's tolerability profile continues to be favorable, despite dose-limiting toxicities observed at the highest dose, leading to optimization of the dosing schedule.

Stakeholder Impact

• **Shareholders**: Potential for value creation if clinical trials succeed, but also risk of dilution from future capital raises (warrants) and ongoing losses. Early clinical data provides some positive signal.
• **Patients**: Potential for new, less toxic, and more effective cancer treatments, especially for those with high unmet medical needs (e.g., Cyclin E over-expression, DDR-related gene mutations, HPV+ tumors).
• **Employees**: Continued employment and progress in drug development.
• **Creditors**: Financial stability supported by cash runway into Q2 2026.

Next Steps

• Continue dose escalation for APR-1051, with enrollment at the 150 mg level.
• Anticipate additional safety and efficacy data from the ACESOT-1051 study (APR-1051) in the second half of 2025.
• Complete the dose-escalation phase for APR-1051 in the first half of 2026.
• Submit an abstract for APR-1051 to a major oncology conference.
• Evaluate APR-1051 in combination with checkpoint inhibitors in future arms of ACESOT-1051.
• Continue dosing ATRN-119 at 400 mg twice daily to refine and optimize therapeutic efficacy and tolerability.
• Expect additional safety and efficacy data from the ABOYA-119 study (ATRN-119) in the second half of 2025.
• Identify the recommended Phase 2 dose (RP2D) for ATRN-119 in the first half of 2026.
• Evaluate ATRN-119 in combination with other therapies in future arms of ABOYA-119.
• Continue preclinical development for an undisclosed macrocyclic DDR inhibitor.
• Evaluate optimal strategic partnerships.

Key Dates

Recommendation

Aprea Therapeutics is a clinical-stage biopharmaceutical company with two lead oncology assets showing early, promising clinical activity and favorable tolerability profiles in Phase 1 studies. The financial results indicate a controlled burn rate and a cash runway into Q2 2026, which is adequate for near-term operations. While the early clinical data are encouraging, they are still preliminary, and the company faces significant risks inherent in drug development, including the need for further successful clinical trials and potential future capital requirements beyond Q2 2026. The observed dose-limiting toxicity for ATRN-119, while common, highlights the ongoing optimization needed. Given the early stage of development and the balance of promising early data against inherent biotech risks and ongoing losses, a 'hold' recommendation is appropriate for investors who are already exposed to the stock, awaiting more mature clinical data and clearer paths to commercialization or partnership. For new investors, it might be prudent to wait for further de-risking through later-stage clinical milestones.

Keywords

Aprea Therapeutics, APRE, Biopharmaceutical, Oncology, Cancer Treatment, Clinical Trials, WEE1 Inhibitor, APR-1051, ATR Inhibitor, ATRN-119, Solid Tumors, HPV-positive, Head and Neck Cancer, Rectal Cancer, Uterine Cancer, DDR Inhibitors, Synthetic Lethality, Financial Results, Drug Development, Phase 1, Phase 2a, Biomarker